Outrun Therapeutics Secures $10M to Advance Protein Stabilisation Technology
Outrun Therapeutics, a Dundee, Scotland, UK-based E3 ligase inhibitor and protein stabilisation developer, recently announced that it has successfully raised $10M in Seed funding. The funding round saw participation from notable investors including M Ventures and MP Healthcare Venture Management. With this influx of capital, the company plans to expand its operations and further enhance its research and development efforts.
Under the leadership of CEO Dr Carolyn Porter, Outrun has pioneered a proprietary platform that enables a comprehensive evaluation of the specificity and selectivity of E3 ligase targets.
This innovative approach not only accelerates the discovery process for E3 ligase inhibitors but also enhances specificity and target binding. By utilizing engineered protein sensors (EPS), Outrun is able to delve into the intricate biochemistry of E3 ligases, ultimately facilitating the development of drugs with superior binding, specificity, and activity. The company's strategy revolves around developing small molecule drugs that target E3 ligases, particularly focusing on inhibitors that stabilize proteins.
In a statement regarding the latest funding round, Dr Carolyn Porter emphasized the significance of protein stabilisation in combating diseases. She highlighted the importance of maintaining optimal levels of crucial proteins that can become imbalanced in certain medical conditions, disrupting the body's natural disease suppression mechanisms. Leveraging their expertise in E3 ligase biology and protein interactions, along with their proprietary discovery platform, Outrun aims to unlock the potential of this emerging therapeutic area. The company's commitment to advancing innovative solutions underscores its dedication to addressing unmet medical needs and improving patient outcomes.
They've invested in Outrun Therapeutics
Get to know these Healthtech investors
| Investors | Investment Focus | Startup Investments | Round Size | Connect |
|---|---|---|---|---|
 M Ventures( ) M Ventures is the strategic corporate venture capital fund of Merck, focusing on... Amsterdam, Netherlands | ||||
 MP Healthcare Venture Management( ) Boston, US  | ||||
| All investors | All investor sectors | All funded startups | All funding rounds |
Click here for a full list of 7,589+ startup investors in the UK